We are live on ! Find out more
PACB icon

Pacific Biosciences
PACB

Fund managers haven’t disclosed any holdings of PACB yet.

PACB Hedge Fund Activity: Q1 2026 in Review

229 of the 8,125 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q1 2026, worth a combined $249M — down 33% from $374M a quarter earlier.

Buyers outnumbered sellers: 52 funds opened new PACB positions and 30 closed out — a net gain of 22 holders — while 60 added to existing stakes and 70 trimmed.

The largest buyer was Nuveen, adding an estimated $3.76M. The largest seller was Casdin Capital, cutting an estimated $6.26M.

  • 229 institutional investors held Pacific Biosciences (PACB) as of Q1 2026, up from 215 in Q4 2025.
  • Funds reported $249M of Pacific Biosciences stock for Q1 2026, down 33% quarter-over-quarter.
  • 52 funds opened new Pacific Biosciences positions in Q1 2026 and 30 closed out, a net change of +22 holders.
  • The largest Pacific Biosciences buyer in Q1 2026 was Nuveen, an estimated $3.76M added.
  • The largest Pacific Biosciences seller in Q1 2026 was Casdin Capital, an estimated $6.26M sold.

Based on aggregated 13F filings for Q1 2026.